<a href="https://laohu8.com/S/AEON">AEON Biopharma</a> Reports No Significant Variation in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Financials, Maintains Cash Runway Through Expected FDA Meeting
AEON Biopharma, Inc. released its financial results for the second quarter ending June 30, 2025. The company reported cash and cash equivalents totaling $8.4 million, which is projected to support its operating plan through the fourth quarter of 2025, including the planned Type 2a meeting with the FDA in the fourth quarter of 2025. AEON Biopharma is progressing toward significant biosimilar development milestones, with the anticipated completion of primary structure analysis and select functional analyses of ABP-450 in the third quarter of 2025. Additionally, the company plans to utilize the 351(k) biosimilar regulatory pathway, using BOTOX® as the reference product. AEON expects the Type 2a meeting with the FDA in the fourth quarter to provide clarity on the development path forward for ABP-450, aiming to enhance patient accessibility to therapeutic neurotoxins.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001837607-25-000065), on August 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。